| abstract |
A substituted tricyclic benzimidazole compound as defined herein by formula (I) or a pharmaceutically acceptable salt thereof is disclosed. The compounds of the invention selectively inhibit CDK8 and are therefore useful in the treatment of diseases associated with this kinase, especially colorectal and melanoma cancers and other solid and hematological malignancies, autoimmune and inflammatory diseases . Methods for preparing these compounds are also disclosed. |